1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Human Plasma-based Hyperimmune Preparation Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Human Plasma-based Hyperimmune Preparation by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Human Plasma-based Hyperimmune Preparation by Country/Region, 2018, 2022 & 2029
2.2 Human Plasma-based Hyperimmune Preparation Segment by Type
2.2.1 Hepatitis B Immunoglobulins
2.2.2 Rabies Immunoglobulins
2.2.3 Tetanus Immunoglobulins
2.2.4 Rho(D) Immunoglobulins
2.2.5 Other
2.3 Human Plasma-based Hyperimmune Preparation Sales by Type
2.3.1 Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Type (2018-2023)
2.3.2 Global Human Plasma-based Hyperimmune Preparation Revenue and Market Share by Type (2018-2023)
2.3.3 Global Human Plasma-based Hyperimmune Preparation Sale Price by Type (2018-2023)
2.4 Human Plasma-based Hyperimmune Preparation Segment by Application
2.4.1 Government Institution
2.4.2 Private Sector
2.4.3 Others
2.5 Human Plasma-based Hyperimmune Preparation Sales by Application
2.5.1 Global Human Plasma-based Hyperimmune Preparation Sale Market Share by Application (2018-2023)
2.5.2 Global Human Plasma-based Hyperimmune Preparation Revenue and Market Share by Application (2018-2023)
2.5.3 Global Human Plasma-based Hyperimmune Preparation Sale Price by Application (2018-2023)
3 Global Human Plasma-based Hyperimmune Preparation by Company
3.1 Global Human Plasma-based Hyperimmune Preparation Breakdown Data by Company
3.1.1 Global Human Plasma-based Hyperimmune Preparation Annual Sales by Company (2018-2023)
3.1.2 Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Company (2018-2023)
3.2 Global Human Plasma-based Hyperimmune Preparation Annual Revenue by Company (2018-2023)
3.2.1 Global Human Plasma-based Hyperimmune Preparation Revenue by Company (2018-2023)
3.2.2 Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Company (2018-2023)
3.3 Global Human Plasma-based Hyperimmune Preparation Sale Price by Company
3.4 Key Manufacturers Human Plasma-based Hyperimmune Preparation Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Plasma-based Hyperimmune Preparation Product Location Distribution
3.4.2 Players Human Plasma-based Hyperimmune Preparation Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Human Plasma-based Hyperimmune Preparation by Geographic Region
4.1 World Historic Human Plasma-based Hyperimmune Preparation Market Size by Geographic Region (2018-2023)
4.1.1 Global Human Plasma-based Hyperimmune Preparation Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Human Plasma-based Hyperimmune Preparation Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Human Plasma-based Hyperimmune Preparation Market Size by Country/Region (2018-2023)
4.2.1 Global Human Plasma-based Hyperimmune Preparation Annual Sales by Country/Region (2018-2023)
4.2.2 Global Human Plasma-based Hyperimmune Preparation Annual Revenue by Country/Region (2018-2023)
4.3 Americas Human Plasma-based Hyperimmune Preparation Sales Growth
4.4 APAC Human Plasma-based Hyperimmune Preparation Sales Growth
4.5 Europe Human Plasma-based Hyperimmune Preparation Sales Growth
4.6 Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales Growth
5 Americas
5.1 Americas Human Plasma-based Hyperimmune Preparation Sales by Country
5.1.1 Americas Human Plasma-based Hyperimmune Preparation Sales by Country (2018-2023)
5.1.2 Americas Human Plasma-based Hyperimmune Preparation Revenue by Country (2018-2023)
5.2 Americas Human Plasma-based Hyperimmune Preparation Sales by Type
5.3 Americas Human Plasma-based Hyperimmune Preparation Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Plasma-based Hyperimmune Preparation Sales by Region
6.1.1 APAC Human Plasma-based Hyperimmune Preparation Sales by Region (2018-2023)
6.1.2 APAC Human Plasma-based Hyperimmune Preparation Revenue by Region (2018-2023)
6.2 APAC Human Plasma-based Hyperimmune Preparation Sales by Type
6.3 APAC Human Plasma-based Hyperimmune Preparation Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Human Plasma-based Hyperimmune Preparation by Country
7.1.1 Europe Human Plasma-based Hyperimmune Preparation Sales by Country (2018-2023)
7.1.2 Europe Human Plasma-based Hyperimmune Preparation Revenue by Country (2018-2023)
7.2 Europe Human Plasma-based Hyperimmune Preparation Sales by Type
7.3 Europe Human Plasma-based Hyperimmune Preparation Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Human Plasma-based Hyperimmune Preparation by Country
8.1.1 Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales by Country (2018-2023)
8.1.2 Middle East & Africa Human Plasma-based Hyperimmune Preparation Revenue by Country (2018-2023)
8.2 Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales by Type
8.3 Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Plasma-based Hyperimmune Preparation
10.3 Manufacturing Process Analysis of Human Plasma-based Hyperimmune Preparation
10.4 Industry Chain Structure of Human Plasma-based Hyperimmune Preparation
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Plasma-based Hyperimmune Preparation Distributors
11.3 Human Plasma-based Hyperimmune Preparation Customer
12 World Forecast Review for Human Plasma-based Hyperimmune Preparation by Geographic Region
12.1 Global Human Plasma-based Hyperimmune Preparation Market Size Forecast by Region
12.1.1 Global Human Plasma-based Hyperimmune Preparation Forecast by Region (2024-2029)
12.1.2 Global Human Plasma-based Hyperimmune Preparation Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Human Plasma-based Hyperimmune Preparation Forecast by Type
12.7 Global Human Plasma-based Hyperimmune Preparation Forecast by Application
13 Key Players Analysis
13.1 CSL Behring
13.1.1 CSL Behring Company Information
13.1.2 CSL Behring Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
13.1.3 CSL Behring Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 CSL Behring Main Business Overview
13.1.5 CSL Behring Latest Developments
13.2 Grifols
13.2.1 Grifols Company Information
13.2.2 Grifols Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
13.2.3 Grifols Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Grifols Main Business Overview
13.2.5 Grifols Latest Developments
13.3 Biotest
13.3.1 Biotest Company Information
13.3.2 Biotest Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
13.3.3 Biotest Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Biotest Main Business Overview
13.3.5 Biotest Latest Developments
13.4 Kedrion
13.4.1 Kedrion Company Information
13.4.2 Kedrion Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
13.4.3 Kedrion Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Kedrion Main Business Overview
13.4.5 Kedrion Latest Developments
13.5 CBPO
13.5.1 CBPO Company Information
13.5.2 CBPO Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
13.5.3 CBPO Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 CBPO Main Business Overview
13.5.5 CBPO Latest Developments
13.6 Emergent (Cangene)
13.6.1 Emergent (Cangene) Company Information
13.6.2 Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
13.6.3 Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Emergent (Cangene) Main Business Overview
13.6.5 Emergent (Cangene) Latest Developments
13.7 Kamada
13.7.1 Kamada Company Information
13.7.2 Kamada Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
13.7.3 Kamada Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Kamada Main Business Overview
13.7.5 Kamada Latest Developments
13.8 CNBG
13.8.1 CNBG Company Information
13.8.2 CNBG Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
13.8.3 CNBG Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 CNBG Main Business Overview
13.8.5 CNBG Latest Developments
13.9 Hualan Bio
13.9.1 Hualan Bio Company Information
13.9.2 Hualan Bio Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
13.9.3 Hualan Bio Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Hualan Bio Main Business Overview
13.9.5 Hualan Bio Latest Developments
13.10 Shanghai RAAS
13.10.1 Shanghai RAAS Company Information
13.10.2 Shanghai RAAS Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
13.10.3 Shanghai RAAS Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Shanghai RAAS Main Business Overview
13.10.5 Shanghai RAAS Latest Developments
13.11 Sichuan Yuanda Shuyang
13.11.1 Sichuan Yuanda Shuyang Company Information
13.11.2 Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
13.11.3 Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Sichuan Yuanda Shuyang Main Business Overview
13.11.5 Sichuan Yuanda Shuyang Latest Developments
13.12 ADMA Biologics
13.12.1 ADMA Biologics Company Information
13.12.2 ADMA Biologics Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
13.12.3 ADMA Biologics Human Plasma-based Hyperimmune Preparation Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 ADMA Biologics Main Business Overview
13.12.5 ADMA Biologics Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Human Plasma-based Hyperimmune Preparation Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Human Plasma-based Hyperimmune Preparation Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Hepatitis B Immunoglobulins
Table 4. Major Players of Rabies Immunoglobulins
Table 5. Major Players of Tetanus Immunoglobulins
Table 6. Major Players of Rho(D) Immunoglobulins
Table 7. Major Players of Other
Table 8. Global Human Plasma-based Hyperimmune Preparation Sales by Type (2018-2023) & (K Units)
Table 9. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Type (2018-2023)
Table 10. Global Human Plasma-based Hyperimmune Preparation Revenue by Type (2018-2023) & ($ million)
Table 11. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Type (2018-2023)
Table 12. Global Human Plasma-based Hyperimmune Preparation Sale Price by Type (2018-2023) & (US$/Unit)
Table 13. Global Human Plasma-based Hyperimmune Preparation Sales by Application (2018-2023) & (K Units)
Table 14. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Application (2018-2023)
Table 15. Global Human Plasma-based Hyperimmune Preparation Revenue by Application (2018-2023)
Table 16. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Application (2018-2023)
Table 17. Global Human Plasma-based Hyperimmune Preparation Sale Price by Application (2018-2023) & (US$/Unit)
Table 18. Global Human Plasma-based Hyperimmune Preparation Sales by Company (2018-2023) & (K Units)
Table 19. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Company (2018-2023)
Table 20. Global Human Plasma-based Hyperimmune Preparation Revenue by Company (2018-2023) ($ Millions)
Table 21. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Company (2018-2023)
Table 22. Global Human Plasma-based Hyperimmune Preparation Sale Price by Company (2018-2023) & (US$/Unit)
Table 23. Key Manufacturers Human Plasma-based Hyperimmune Preparation Producing Area Distribution and Sales Area
Table 24. Players Human Plasma-based Hyperimmune Preparation Products Offered
Table 25. Human Plasma-based Hyperimmune Preparation Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Human Plasma-based Hyperimmune Preparation Sales by Geographic Region (2018-2023) & (K Units)
Table 29. Global Human Plasma-based Hyperimmune Preparation Sales Market Share Geographic Region (2018-2023)
Table 30. Global Human Plasma-based Hyperimmune Preparation Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global Human Plasma-based Hyperimmune Preparation Sales by Country/Region (2018-2023) & (K Units)
Table 33. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Country/Region (2018-2023)
Table 34. Global Human Plasma-based Hyperimmune Preparation Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas Human Plasma-based Hyperimmune Preparation Sales by Country (2018-2023) & (K Units)
Table 37. Americas Human Plasma-based Hyperimmune Preparation Sales Market Share by Country (2018-2023)
Table 38. Americas Human Plasma-based Hyperimmune Preparation Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas Human Plasma-based Hyperimmune Preparation Revenue Market Share by Country (2018-2023)
Table 40. Americas Human Plasma-based Hyperimmune Preparation Sales by Type (2018-2023) & (K Units)
Table 41. Americas Human Plasma-based Hyperimmune Preparation Sales by Application (2018-2023) & (K Units)
Table 42. APAC Human Plasma-based Hyperimmune Preparation Sales by Region (2018-2023) & (K Units)
Table 43. APAC Human Plasma-based Hyperimmune Preparation Sales Market Share by Region (2018-2023)
Table 44. APAC Human Plasma-based Hyperimmune Preparation Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC Human Plasma-based Hyperimmune Preparation Revenue Market Share by Region (2018-2023)
Table 46. APAC Human Plasma-based Hyperimmune Preparation Sales by Type (2018-2023) & (K Units)
Table 47. APAC Human Plasma-based Hyperimmune Preparation Sales by Application (2018-2023) & (K Units)
Table 48. Europe Human Plasma-based Hyperimmune Preparation Sales by Country (2018-2023) & (K Units)
Table 49. Europe Human Plasma-based Hyperimmune Preparation Sales Market Share by Country (2018-2023)
Table 50. Europe Human Plasma-based Hyperimmune Preparation Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe Human Plasma-based Hyperimmune Preparation Revenue Market Share by Country (2018-2023)
Table 52. Europe Human Plasma-based Hyperimmune Preparation Sales by Type (2018-2023) & (K Units)
Table 53. Europe Human Plasma-based Hyperimmune Preparation Sales by Application (2018-2023) & (K Units)
Table 54. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales by Country (2018-2023) & (K Units)
Table 55. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa Human Plasma-based Hyperimmune Preparation Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa Human Plasma-based Hyperimmune Preparation Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales by Type (2018-2023) & (K Units)
Table 59. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales by Application (2018-2023) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of Human Plasma-based Hyperimmune Preparation
Table 61. Key Market Challenges & Risks of Human Plasma-based Hyperimmune Preparation
Table 62. Key Industry Trends of Human Plasma-based Hyperimmune Preparation
Table 63. Human Plasma-based Hyperimmune Preparation Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Human Plasma-based Hyperimmune Preparation Distributors List
Table 66. Human Plasma-based Hyperimmune Preparation Customer List
Table 67. Global Human Plasma-based Hyperimmune Preparation Sales Forecast by Region (2024-2029) & (K Units)
Table 68. Global Human Plasma-based Hyperimmune Preparation Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas Human Plasma-based Hyperimmune Preparation Sales Forecast by Country (2024-2029) & (K Units)
Table 70. Americas Human Plasma-based Hyperimmune Preparation Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC Human Plasma-based Hyperimmune Preparation Sales Forecast by Region (2024-2029) & (K Units)
Table 72. APAC Human Plasma-based Hyperimmune Preparation Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe Human Plasma-based Hyperimmune Preparation Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Europe Human Plasma-based Hyperimmune Preparation Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales Forecast by Country (2024-2029) & (K Units)
Table 76. Middle East & Africa Human Plasma-based Hyperimmune Preparation Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global Human Plasma-based Hyperimmune Preparation Sales Forecast by Type (2024-2029) & (K Units)
Table 78. Global Human Plasma-based Hyperimmune Preparation Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global Human Plasma-based Hyperimmune Preparation Sales Forecast by Application (2024-2029) & (K Units)
Table 80. Global Human Plasma-based Hyperimmune Preparation Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. CSL Behring Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors
Table 82. CSL Behring Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
Table 83. CSL Behring Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 84. CSL Behring Main Business
Table 85. CSL Behring Latest Developments
Table 86. Grifols Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors
Table 87. Grifols Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
Table 88. Grifols Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 89. Grifols Main Business
Table 90. Grifols Latest Developments
Table 91. Biotest Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors
Table 92. Biotest Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
Table 93. Biotest Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 94. Biotest Main Business
Table 95. Biotest Latest Developments
Table 96. Kedrion Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors
Table 97. Kedrion Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
Table 98. Kedrion Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 99. Kedrion Main Business
Table 100. Kedrion Latest Developments
Table 101. CBPO Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors
Table 102. CBPO Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
Table 103. CBPO Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 104. CBPO Main Business
Table 105. CBPO Latest Developments
Table 106. Emergent (Cangene) Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors
Table 107. Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
Table 108. Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 109. Emergent (Cangene) Main Business
Table 110. Emergent (Cangene) Latest Developments
Table 111. Kamada Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors
Table 112. Kamada Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
Table 113. Kamada Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 114. Kamada Main Business
Table 115. Kamada Latest Developments
Table 116. CNBG Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors
Table 117. CNBG Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
Table 118. CNBG Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 119. CNBG Main Business
Table 120. CNBG Latest Developments
Table 121. Hualan Bio Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors
Table 122. Hualan Bio Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
Table 123. Hualan Bio Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 124. Hualan Bio Main Business
Table 125. Hualan Bio Latest Developments
Table 126. Shanghai RAAS Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors
Table 127. Shanghai RAAS Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
Table 128. Shanghai RAAS Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 129. Shanghai RAAS Main Business
Table 130. Shanghai RAAS Latest Developments
Table 131. Sichuan Yuanda Shuyang Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors
Table 132. Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
Table 133. Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 134. Sichuan Yuanda Shuyang Main Business
Table 135. Sichuan Yuanda Shuyang Latest Developments
Table 136. ADMA Biologics Basic Information, Human Plasma-based Hyperimmune Preparation Manufacturing Base, Sales Area and Its Competitors
Table 137. ADMA Biologics Human Plasma-based Hyperimmune Preparation Product Portfolios and Specifications
Table 138. ADMA Biologics Human Plasma-based Hyperimmune Preparation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 139. ADMA Biologics Main Business
Table 140. ADMA Biologics Latest Developments
List of Figures
Figure 1. Picture of Human Plasma-based Hyperimmune Preparation
Figure 2. Human Plasma-based Hyperimmune Preparation Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Human Plasma-based Hyperimmune Preparation Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Human Plasma-based Hyperimmune Preparation Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Human Plasma-based Hyperimmune Preparation Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Hepatitis B Immunoglobulins
Figure 10. Product Picture of Rabies Immunoglobulins
Figure 11. Product Picture of Tetanus Immunoglobulins
Figure 12. Product Picture of Rho(D) Immunoglobulins
Figure 13. Product Picture of Other
Figure 14. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Type in 2022
Figure 15. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Type (2018-2023)
Figure 16. Human Plasma-based Hyperimmune Preparation Consumed in Government Institution
Figure 17. Global Human Plasma-based Hyperimmune Preparation Market: Government Institution (2018-2023) & (K Units)
Figure 18. Human Plasma-based Hyperimmune Preparation Consumed in Private Sector
Figure 19. Global Human Plasma-based Hyperimmune Preparation Market: Private Sector (2018-2023) & (K Units)
Figure 20. Human Plasma-based Hyperimmune Preparation Consumed in Others
Figure 21. Global Human Plasma-based Hyperimmune Preparation Market: Others (2018-2023) & (K Units)
Figure 22. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Application (2022)
Figure 23. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Application in 2022
Figure 24. Human Plasma-based Hyperimmune Preparation Sales Market by Company in 2022 (K Units)
Figure 25. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Company in 2022
Figure 26. Human Plasma-based Hyperimmune Preparation Revenue Market by Company in 2022 ($ Million)
Figure 27. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Company in 2022
Figure 28. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Geographic Region (2018-2023)
Figure 29. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share by Geographic Region in 2022
Figure 30. Americas Human Plasma-based Hyperimmune Preparation Sales 2018-2023 (K Units)
Figure 31. Americas Human Plasma-based Hyperimmune Preparation Revenue 2018-2023 ($ Millions)
Figure 32. APAC Human Plasma-based Hyperimmune Preparation Sales 2018-2023 (K Units)
Figure 33. APAC Human Plasma-based Hyperimmune Preparation Revenue 2018-2023 ($ Millions)
Figure 34. Europe Human Plasma-based Hyperimmune Preparation Sales 2018-2023 (K Units)
Figure 35. Europe Human Plasma-based Hyperimmune Preparation Revenue 2018-2023 ($ Millions)
Figure 36. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales 2018-2023 (K Units)
Figure 37. Middle East & Africa Human Plasma-based Hyperimmune Preparation Revenue 2018-2023 ($ Millions)
Figure 38. Americas Human Plasma-based Hyperimmune Preparation Sales Market Share by Country in 2022
Figure 39. Americas Human Plasma-based Hyperimmune Preparation Revenue Market Share by Country in 2022
Figure 40. Americas Human Plasma-based Hyperimmune Preparation Sales Market Share by Type (2018-2023)
Figure 41. Americas Human Plasma-based Hyperimmune Preparation Sales Market Share by Application (2018-2023)
Figure 42. United States Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 43. Canada Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 44. Mexico Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 45. Brazil Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 46. APAC Human Plasma-based Hyperimmune Preparation Sales Market Share by Region in 2022
Figure 47. APAC Human Plasma-based Hyperimmune Preparation Revenue Market Share by Regions in 2022
Figure 48. APAC Human Plasma-based Hyperimmune Preparation Sales Market Share by Type (2018-2023)
Figure 49. APAC Human Plasma-based Hyperimmune Preparation Sales Market Share by Application (2018-2023)
Figure 50. China Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 51. Japan Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 52. South Korea Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 53. Southeast Asia Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 54. India Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 55. Australia Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 56. China Taiwan Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 57. Europe Human Plasma-based Hyperimmune Preparation Sales Market Share by Country in 2022
Figure 58. Europe Human Plasma-based Hyperimmune Preparation Revenue Market Share by Country in 2022
Figure 59. Europe Human Plasma-based Hyperimmune Preparation Sales Market Share by Type (2018-2023)
Figure 60. Europe Human Plasma-based Hyperimmune Preparation Sales Market Share by Application (2018-2023)
Figure 61. Germany Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 62. France Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 63. UK Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 64. Italy Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 65. Russia Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 66. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales Market Share by Country in 2022
Figure 67. Middle East & Africa Human Plasma-based Hyperimmune Preparation Revenue Market Share by Country in 2022
Figure 68. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales Market Share by Type (2018-2023)
Figure 69. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales Market Share by Application (2018-2023)
Figure 70. Egypt Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 71. South Africa Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 72. Israel Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 73. Turkey Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 74. GCC Country Human Plasma-based Hyperimmune Preparation Revenue Growth 2018-2023 ($ Millions)
Figure 75. Manufacturing Cost Structure Analysis of Human Plasma-based Hyperimmune Preparation in 2022
Figure 76. Manufacturing Process Analysis of Human Plasma-based Hyperimmune Preparation
Figure 77. Industry Chain Structure of Human Plasma-based Hyperimmune Preparation
Figure 78. Channels of Distribution
Figure 79. Global Human Plasma-based Hyperimmune Preparation Sales Market Forecast by Region (2024-2029)
Figure 80. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share Forecast by Region (2024-2029)
Figure 81. Global Human Plasma-based Hyperimmune Preparation Sales Market Share Forecast by Type (2024-2029)
Figure 82. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share Forecast by Type (2024-2029)
Figure 83. Global Human Plasma-based Hyperimmune Preparation Sales Market Share Forecast by Application (2024-2029)
Figure 84. Global Human Plasma-based Hyperimmune Preparation Revenue Market Share Forecast by Application (2024-2029)

※参考情報 ヒト血漿ベース高度免疫製剤は、特定の感染症や病態に対する強力な免疫応答を引き出すために、主にヒト血漿から製造される治療薬です。これらの製剤は、主に抗体を含む免疫グロブリンを中心に構成されており、特定のウイルスや細菌に対する防御能力を強化することを目的としています。高度免疫製剤は、主に患者の免疫力が低下している場合や特定の感染症に対する早急な対応が必要な場合に使用されます。 ヒト血漿は、血液中の液体成分であり、血球成分を除いた状態で様々なタンパク質、電解質やホルモンを含んでいます。この中で特に注目されるのが免疫グロブリンで、これは体内に侵入した病原体に対する抗体としての役割を果たします。高度免疫製剤は、特定の病原体に対する抗体を多量に含むように処理・精製され、患者に投与されることで、免疫系をサポートします。 この製剤の大きな特徴は、免疫反応を迅速に導く能力です。感染症にかかった患者や高リスク群の場合、速やかに抗体を供給することが求められます。通常、これらの製剤は免疫グロブリンの濃度が高く、特定の病原体に対して特異的な抗体が豊富に含まれています。これにより、患者の免疫系が抗原に迅速に応答し、感染症に対して抵抗力を高めることが期待されます。 高度免疫製剤の種類には、以下のようなものがあります。まず、免疫グロブリン製剤は一般的に知られたカテゴリーであり、これには免疫グロブリンG（IgG）、免疫グロブリンA（IgA）、免疫グロブリンM（IgM）などが含まれます。これらは特定の病原体に対応したものだけでなく、一般的な感染症に対する防御力を強化する役割も果たします。 さらに、特定の病原体に対する高度免疫製剤としては、例えばB型肝炎ウイルスや新型コロナウイルス、RSウイルスなどに対するものがあります。これらは選択的に特定の抗体を濃縮し、感染症の予防や治療に用いられます。また、特定のウイルスや細菌に対する特異的抗体を集中的に含む製剤は、急性の感染症に対して特に効果的です。 このような製剤は、様々な用途に応じて利用されます。主な用途としては、免疫不全患者に対する抗体補充療法があります。これにより、患者の感染症に対する防御を強化し、合併症のリスクを減少させることができます。また、特定の感染症の流行時には、予防策として用いられることもあります。例えば、新型コロナウイルス感染症のパンデミック時には、COVID-19に対する高度免疫血漿が一時的に治療に用いられました。 関連技術としては、製剤を製造するための高度な血漿分画法や精製技術が挙げられます。これには超遠心分離や親和性クロマトグラフィーなどが含まれ、より高純度の免疫グロブリンを得るための手法として重要です。また、これらの製剤に対する評価方法も進化しており、抗体の特異性や affinities を測定するための技術が開発されています。これにより、より効果的な製剤の開発が促進され、臨床応用に向けた期待が高まっています。 ヒト血漿ベース高度免疫製剤は、感染症治療において重要な役割を果たしていますが、その生産には倫理的な配慮も必要です。血漿の提供者を尊重し、採取から製剤までの過程において安全性を確保することが求められています。特に、血漿供給者の健康状態や献血の適格性について十分なチェックが行われることが重要です。 さらに、今後の研究や技術革新により、より効果的で安全な製剤が開発されることが期待されています。新しい疾患に対する反応や、不断に変異する病原体に対抗するための新しいアプローチが模索されています。例えば、マイクロバイオームや遺伝子工学を用いた新しい治療戦略が進行中です。これにより、今後ますます多様な疾病に対する治療の選択肢が広がるとともに、患者のQOL（生活の質）向上に寄与することが期待されています。 ヒト血漿ベース高度免疫製剤は、感染症に対する重要な治療戦略であり、様々な病状に応じた適切な選択と利用が求められます。その役割は今後とも拡大することが予想され、より多くの患者に対して新たな希望をもたらすことが期待されています。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer